latest-news-headlines Market Intelligence /marketintelligence/en/news-insights/latest-news-headlines/shanghai-fosun-receives-emergency-approval-in-china-for-covid-19-test-57775166 content esgSubNav
In This List

Shanghai Fosun receives emergency approval in China for COVID-19 test

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery


Shanghai Fosun receives emergency approval in China for COVID-19 test

Shanghai Fosun Pharmaceutical (Group) Co. Ltd. received emergency approval from China's National Medical Products Administration for its test to detect the novel coronavirus.

The Shanghai-based pharmaceutical company said its test kit detects gene targets of the virus and can complete an analysis of 96 samples in two hours.

Fosun's coronavirus nucleic acid detection kit conducts automated testing that lowers the risk of infections and cross-contamination.

Globally, COVID-19 has infected more than 492,000 people and caused over 22,200 deaths as of March 26, according to data from Johns Hopkins University's Center for Systems Science and Engineering.

READ MORE: Sign up for our weekly coronavirus newsletter here, and read our latest coverage on the crisis here.